CING

Cingulate Inc. - Common Stock (CING)

About Cingulate Inc. - Common Stock (CING)

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Details

Daily high

$5.48

Daily low

$5.21

Price at open

$5.27

52 Week High

$11.89

52 Week Low

$3.16

Market cap

76.2M

Dividend yield

Volume

21,751

Avg. volume

116,876

P/E ratio

-1.45

Cingulate Inc. - Common Stock News